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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S139patients who received 3 x 106/kg haplo-CD34+ cells, & 26 &
18 days in 2 patients who received 1 x 106/kg haplo-CD34+
cells. Platelet recovery occurred in 13/16 patients (median 26
days, range 17-46). While day 14 myeloid recovery was
predominantly haplo-mediated, one CB unit dominated by
day 28 in both neutrophil & T-cell subsets (Table). By day 60,
the median total donor chimerism was 100% the dominant
CB unit. With a median survivor follow-up of 7 months
(range 3-12),12/16 patients developed gr. II-IV aGVHD by day
100 (10 gr. II, 1 gr. III, 1 gr. IV). One refractory leukemia patient
relapsed & 5 had TRM (3 organ failure, 1 grade IV aGVHD, 1
CMV infection). Surviving patients were discharged at a 33
day median (9 days faster than DCBT controls).
Conclusions: Double-unit CBT with haplo-CD34+ cells is safe
& neutrophil engraftment is enhanced. A shorter initial
hospitalization offsets the haplo-CD34+ cell cost. It is
intriguing that the dominant CB unit can rapidly reject the
haplo-identical donor. Whether the same results could be
achievedwith single CB units, and whether myeloid recovery
could be further enhanced by a higher haplo-CD34+ cell
dose, require investigation.190
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Background: Availability of suitably HLA-matched unrelated
donors (URD) is a major barrier to allogeneic transplantation
and CB can extend transplant access. We evaluated if URD/
CB access has improved with increased size of URD registries
& global CB inventories.
Methods: We prospectively collected ancestry data on
patients undergoing searches between 10/2005-6/2013, &
analyzed the availability of 9-10/10 HLA-matched URDs or
4-6/6 HLA-A,-B antigen, -DRB1 allele matched CB units by
recipient ancestry. 10 HLA-allele matched URDs were
given priority if available; otherwise HLA-mismatched
URDs or double-unit CB grafts were chosen. This analysis
was restricted to CB units with a cryo. TNC dose > 2.0.
Availability of CB units by 10-allele match was also
evaluated.Early Time Period
(n ¼ 424, 60% of total)
Recent Time Period
(n ¼ 284, 40% of total)
Europeans (n ¼ 485)
N ¼ 295 N ¼ 190
URD: 246 (71% 10/10) URD: 154 (76% 10/10)
CB: 42 (48%  6/10) CB: 35 (54%  6/10)
No graft: 7 (2%) No graft: 1 (0.5%)
Non-Europeans (n ¼ 223)
N ¼ 129 N ¼ 94
URD: 61 (48% 10/10) URD: 50 (56% 10/10)
CB: 46 (28%  6/10) CB: 36 (69%  6/10)
No graft: 22 (17%) No graft: 8 (8.5%)Results: Of 708 patients, 223 (31%) were non-European. URD
recipients were predominantly European (400/511, 78%)
whereas only 77/159 (48%) of CB recipients had European
origins. 30/38 (79%) “no graft” patients were non-European
(including 20 African ancestry patients), and they had a
higher weight (median 93 kg) than CB recipients, p < 0.001.
Graft availability during early (10/2005-12/2010) vs recent
(1/2011-6/2013) periods is shown (Table). Ancestry distri-
bution was equal during the periods. Of all early vs late
period patients, less than two-thirds of Europeans received a
10/10 URD in both eras (59% vs 61%) but very few had no graft
(< 1% recently). However, of non-Europeans in the early
period overall, only 29/129 (22%) had a 10/10 URD, & this has
not improved [28/94 (30%), p¼ 0.28]. While only 28% of non-
Europeans received  6/10 CB units in the early period, this
match rate improved to 69% recently (p < 0.001). The per-
centage of non-Europeans with no graft has decreased from
17% to 8.5% recently (p ¼ 0.08). Of African patients without
an URD, 16/31 (52%) had a CB graft in the early period vs 15/
20 (75%) recently, p ¼ 0.14.
Conclusion: Less than two-thirds of Europeans have a 10/10
URD, but very few do not have an URD &/or CB graft. CB,
unlike URDs, is a critically important donor source for mi-
norities, & transplantation of CB units with higher rates of 10
HLA-allele match is possible. Improved CB availability in
non-Europeans is suggested but an enlarged inventory is
required to extend access, especially for African ancestry
patients.191
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The Killer immunoglobulin-like receptor (KIR) genetic
system is polygenic and highly polymorphic. Several studies
conﬁrmed the KIR haplotype associationwith hematopoietic
stem cell transplant (HSCT) outcome, however, KIR haplo-
type assignment using KIR genotypes, is still a challenge even
with family information available, because KIR haplotypes
may vary in gene copy-number, gene content and allelic
diversity.
The goal of the present study is to assign KIR haplotypes in
related HSCT patient-donor pairs using next generation
sequencing (NGS) method.
We selected 10 families (n¼38 in total): 6 with both parents
available. All of them were previously typed with SSP-
Multiplex for KIR genotyping and Sequencing for 3DL1/2/3
alleles. Scisco KIR NGS method can distinguish KIR geno-
types, calculate gene copy number, estimate gene-content
haplotypes and assign KIR alleles.
KIR genotypes obtained with two methods:SSP and NGS
were identical. We are able to distinguish KIR haplotype
distribution within families. KIR gene copy number is
essential in this regard. However, if a sibling pair are both KIR
AA genotype, it is difﬁcult to distinguish KIR haplotype
matching, without KIR allele information. KIR allele assign-
ments are in progress.192
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